Subcutaneous Drug Delivery Devices Market - Forecast(2024 - 2030)

Subcutaneous Drug Delivery Devices Market Overview

Subcutaneous Drug Delivery Devices Market size is estimated to reach $17.2 billion by 2027, growing at a CAGR of 8.4% during the forecast period 2022-2027. The word Subcutaneous can be defined with the phrase “under the skin.” Therefore, subcutaneous drugs are the medications that are interleaved under the skin of patients with the assistance of subcutaneous devices such as needle-free injectors or syringes in order to cure the sickness inflicting them. Drugs injected in this way absorb slowly as they are inoculated into tissue sheets lying amid the muscle and the membrane not unswervingly hooked on the veins. Wearable injectors have come to the foreground in contemporary times as they can inject a large number of drugs at one go. Consequently, taking these privileges and other factors; upsurge in transmissible, and cardiovascular diseases such as; arrhythmia (=improper heart beating), heart attack, coronary ailments which devastate prime plasma vessel in the heart into account the overall outlook for subcutaneous drug delivery devices market is fairly captivating. Intensification in vigor hitches, the convenience of advanced expertise is set to drive the growth of the Subcutaneous Drug Delivery Devices Industry for the period 2022-2027.

Report Coverage:

The report: “Subcutaneous Drug Delivery Devices Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Subcutaneous Drug Delivery Devices Market.

Key Takeaways:

• Geographically, the North America Subcutaneous Drug Delivery Devices Market accounted for the highest revenue share in 2021 owing to the awareness in native people, discoveries in biomedicine, availability of advanced technology possessed medical tools. Additionally, the Asia-Pacific is estimated to offer lucrative growth opportunities to the marketers in the projected period of 2022-2027 owing to the rising diabetic population supplemented by the growing senior population.
• Needle-free injectors and wearable injectors are the best things since sliced bread in the medical field as they mitigate even the slightest possibility of pain due to hypodermics and are one of the major factors that are said to fuel the growth. Pain and health concerns ascribed with drug injections through hypodermic may reduce the growth of the Subcutaneous Drug Delivery Devices Market.
• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Subcutaneous Drug Delivery Devices Market report.

Subcutaneous Drug Delivery Devices Market Share, By Technology, 2021(%)

For more details on this report - Request for Sample

Subcutaneous Drug Delivery Devices Market Segment Analysis-By Technology 

The Subcutaneous Drug Delivery Devices Market based on technology can be further segmented into Hypodermics/Syringes (e.g., =Dental, lure Lock Tip, Withdrawal syringes, Insulin, etc.), Wearable Injectors (e.g., =Patches), autoinjectors, pens, and needle-free Injectors. The Pen injector segment held the largest share in 2021 owing to the factors such as increased home usage of patches, pen, and needle-free injectors as their east to use nature, needle-free injectors giving liberty to injection phobic patients to elude the pain. Moreover, the pandemic made a lot of patients depend on the monoclonal antibodies, as their life was hanging in the balance. The following is delivered via subcutaneous route as they contain big of a molecule which cannot be ingested by a person. The U.S. saw a 1,200% increment in order for monoclonal antibodies owing to the pandemic.

However, the Wearable Injectors and needle-free injector segment are estimated to be the fastest-growing segment with a CAGR of 9.1% over the period 2022-2027. This growth is owing to factors such as mitigation of apprehensions related to the peril of side effects posed by the usage of needles in syringes to supplement drugs, painless process, environment friendly as wearable patches are easy to dispose of as compared to hard body syringes.

Subcutaneous Drug Delivery Devices Market Segment Analysis-By Distribution Channel

The Subcutaneous Drug Delivery Devices Market based on the distribution channel can be further segmented into Hospitals, Health Centers, Local Medical Stores/Retail Pharmacies, Online Pharmacies. The Medical Stores/Retail Pharmacies Market segment held the largest share in 2021 owing to the factors such as extensive existence covering all zones even trivial conurbations or pastoral parts, upsurge in transmittable sicknesses after the outbreak of COVID-19, subordinate capital prerequisite equivalence to intensive conveniences such as Health centers or private Hospitals.

Online Pharmacies are estimated to be the fastest-growing segment with a CAGR of 9.2% over the period 2022-2027. This growth is owing to expedite push toward digitalization in both developed and developing countries, elegant shopping, and doorstep deliveries which save plenty of time and of expedient landscape, hefty current of funds in E-commerce taming digital health infrastructure. For example, Lantus, an insulin medication supposed to be delivered via subcutaneous route for long-lasting effect, is available for INR 527 against the MRP of 722 on the 1MG platform. Owing to such price differential and other lucrative cashback or discount policies- the segment would register steadfast growth.

Subcutaneous Drug Delivery Devices Market Segment Analysis-By Geography

The Subcutaneous Drug Delivery Devices based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 36% of the overall market in 2021. The growth in this segment is owing to the factors such as High health perception in western society, affluence in contagious maladies, Well-heeled GDPs of North American nations such US and Canada ensuing in a redundant drift of capital in healthcare infrastructure, lofty living standards. As per HHS, nearly 600,000 people within the U.S. have received antibody treatment since the advent of pandemics.

However, the Asia-Pacific is estimated to offer lucrative growth opportunities to marketers over the forecast period 2022-2027. This growth is owing to the gigantic population, and elderly population fueling the prevalence of communicable diseases, bizarre assimilation behaviors, swelling population fueling the outbreak of infections, ameliorating healthcare, and hegemony in medicine manufacturing of countries like India and China.

Subcutaneous Drug Delivery Devices Market Drivers

Huge revenue in bacterial sampling is projected to drive market growth.

Infections, viruses, and ailments associated with them are predominating around the globe at a sturdy pace due to poor ingestion habits, dwindling immunity, this market has come to the foreground as a lucrative destination for businesses and R&D companies. In 2019 There were around 400-500 million people were affected with Chronic disease diabetes and expected to reach 600-700 million in near future. As the future seems appealing various players in the subcutaneous market sense it and running to clutch an opportunity to reap remunerations. Moreover, the various government tactics and schemes to shape better health infrastructure to bout contingencies like COVID-19 propelling the market forward.

Technological breakthroughs are Projected to Drive Market Growth.

Technological breakthroughs are casting votes in favor of the subcutaneous Drug delivery Market as new discoveries are making it easy to diagnose and treat ailments in a productive way. Discoveries such as wearable injectors (= patches, which easily disseminate the drugs under the skin of patients without any need of hypodermics, needle-free injectors are proving to be a benediction for people inflicted with injection phobia are the factors uplifting the market. As of Nov 12, 2021, 19 investigational antibody therapeutics are in regulatory review in either the US or EU. During January 1 to Nov 12, 2021, 11 antibody therapeutics were granted first approvals in either the US or EU.

Subcutaneous Drug Delivery Devices Market Challenges

Injection phobia and health problems associated with needle injectors are Anticipated to Hamper Market Growth to some extent. 

Many people possess a nervous disposition and are naturally prone to injection phobia. They get anxious at the sight of needles. Needle-free injections are in the market but still not at a larger scale as it’s a new discovery. Still, more than 65% of the market share is captured by prefilled Syringes. Moreover, various side effects of using needles to inject drugs such as infection, developing cancer cells overtime provided the needle is contaminated. Therefore, people may develop a slight loathe toward it and it can hamper the market.

Subcutaneous Drug Delivery Devices Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Subcutaneous Drug Delivery Devices Market. Subcutaneous Drug Delivery Devices top 10 companies include:

1. Insulet Corporation
2. Indolife Sciences
3. Medtronic Plc
4. Novo Nordisk
5. Gerresheimer AG
6. Elcam Medical Group
7. Dickinson and Company
8. Elcam Medical Group
9. Medtronic Plc
10. PharmaJet

Partnerships/Product Launches:

• On November 3, 2021, a German-based company Grerresheimer claimed to develop a subcutaneous drug delivery device named “SensAIR” which is proficient in injecting drugs with a higher viscosity than normal drugs. The product would allow for the delivery of monoclonal antibodies for volumes that are beyond pens and autoinjectors. The product gets loaded with a cartridge, which gets attached to the body and one needs to activate the device. By the end, the patient can detach the device.
• On April 20, 2021, Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations announced a collaboration and license agreement with argenx to explore new subcutaneous formulations for therapeutic products directed at the human neonatal Fc receptor (FcRn), including efgartigimod, and up to one additional target. Within the agreement norms, Argenx will have to make an upfront payment and future milestones payments of pre-defined development, regulatory, and commercial milestones.
• On March 2, 2021, ReForm taps the ex-Genzyme exec to lead the subcutaneous delivery strategy. The name of the person in Jim Sherblom, to enhance the focus on the development of subcutaneous versions of intravenous products. For allowing such an intervention strategy, ReForm aims to improve treatment adherence through formulations that are more convenient and are in turn flexible.

Relevant Links: